X

Vous n'êtes pas connecté

Maroc Maroc - HAEI.ORG - A La Une - 12/Aug 08:18

Astria chooses Ypsomed’s YpsoMate as injection device for STAR-0215 for treatment of HAE

Astria Therapeutics chooses Ypsomed’s YpsoMate as the injection device for STAR-0215 for the treatment of hereditary angioedema Astra Therapeutics announced that it has chosen Ypsomed as its partner for the development of an autoinjector for STAR-0215. John Ruesch, Senior Vice President, Pharmaceutical Sciences and Technical Operations at Astria, said: “With STAR-0215's profile, our goal [...]

Articles similaires

Sorry! Image not available at this time

Astria to present at upcoming Bradykinin Symposium

haei.org - 30/Aug 11:26

Astria to present at upcoming Bradykinin Symposium Astra Therapeutics announced that it will present two posters at the upcoming Bradykinin Symposium...

Sorry! Image not available at this time

Astria to present at upcoming Bradykinin Symposium

haei.org - 30/Aug 11:26

Astria to present at upcoming Bradykinin Symposium Astra Therapeutics announced that it will present two posters at the upcoming Bradykinin Symposium...

Sorry! Image not available at this time

KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE

haei.org - 03/Sep 17:29

KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...

Sorry! Image not available at this time

Pharvaris presents deucrictibant long-term extension data for both the prophylactic and on-demand treatment of HAE at the Bradykinin Symposium 2024

haei.org - 05/Sep 18:45

Pharvaris presents deucrictibant long-term extension data for both the prophylactic and on-demand treatment of HAE at the Bradykinin Symposium 2024...

Sorry! Image not available at this time

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

drugs.com - 03/Sep 20:09

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....

Sorry! Image not available at this time

Pharvaris provides business update and expands development program for deucrictibant

haei.org - 05/Sep 18:44

Pharvaris provides business update and expands development program for deucrictibant Pharvaris today announced: The planned initiation of CHAPTER-3,...

Sorry! Image not available at this time

BioCryst presents new Orladeyo (berotralstat) data at 7th Bradykinin Symposium

haei.org - 06/Sep 18:48

BioCryst presents new Orladeyo (berotralstat) data at 7th Bradykinin Symposium BioCryst Pharmaceuticals today announced the presentation of six...

Revive Therapeutics Considers Exploring Bucillamine For Treatment Of Monkeypox

thedeepdive.ca - 29/Aug 14:31

Revive Therapeutics (CSE: RVV) is continuing its efforts into evaluating the uses of Bucillamine, disclosing yesterday an update to its The post...

Les derniers communiqués

  • Aucun élément